Insulet Corporation $PODD Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its holdings in Insulet Corporation (NASDAQ:PODD) by 712.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 318,848 shares of the medical instruments supplier’s stock after purchasing an additional 279,587 shares during the period. SG Americas Securities LLC owned 0.46% of Insulet worth $66,907,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its stake in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the 4th quarter valued at about $28,000. DV Equities LLC purchased a new position in shares of Insulet during the 4th quarter worth about $28,000. Finally, MV Capital Management Inc. purchased a new position in shares of Insulet during the 4th quarter worth about $29,000.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Insulet Stock Down 4.7%

PODD opened at $138.97 on Tuesday. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm has a 50 day moving average price of $162.97 and a 200 day moving average price of $224.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The company has a market cap of $9.63 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the previous year, the company posted $1.02 earnings per share. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of recent analyst reports. Bank of America lowered their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Barclays cut their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Canaccord Genuity Group decreased their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. UBS Group set a $219.00 price objective on shares of Insulet in a research note on Thursday, June 11th. Finally, Raymond James Financial set a $216.00 price objective on Insulet in a report on Monday, June 8th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $240.78.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.